Dublin-listed Merrion Pharmaceuticals has announced it has had a US patent granted for technology relating to its GIPET system, which delivers drugs across the small intestine.
A United States Patent No. 7,658,938 was issued for Merrion’s ‘Solid Oral Dosage Form Containing an Enhancer’, the pharmaceutical company said.
“This is a significant development for Merrion’s GIPET technology. The continued growth of our patent estate further establishes us as one of the leading companies in this space,” said Merrion CEO John Lynch.
“Merrion’s GIPET technology has been validated in several products, demonstrating that we deliver real value to patients and healthcare providers.
“This US patent is another step towards achieving our overall vision,” Lynch added.
A patent covering the GIPET technology, including its use with bisphosphonates, has already been granted in Europe.
Article courtesy of Businessandleadership.com
Photo: Merrion Pharmaceuticals has been granted a US patent for its ‘Solid Oral Dosage Form Containing an Enhancer’, which delivers drugs across the small intestine
